News 
Market Data 
Discover
GrthzGd
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
| Ticker | Board | News | Price | Change | Chg% | Added | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ACAD | Acadia Pharmaceuticals Inc. | 15.44 | 0.23 | 1.51% | 06/22/2017 | |||||
|
My ACAD Pitch: Nuplazid, the first approved treatment for Parkinson's psychosis, is now in P3 trials for schizophrenia, and in P2 as treatment for Alzheimer's psychosis, Alzheimer's agitation and for depression.
|
||||||||||
| ENTA | Enanta Pharmaceuticals Inc | 12.64 | -0.29 | -2.24% | 01/28/2014 | |||||
|
My ENTA Pitch: Anti-viral drugs on the verge of, with ABBV's components, curing most strains of Hepatitis C
|
||||||||||
| HAL | Halliburton Company | 37.1 | -0.38 | -1.01% | 01/05/2012 | |||||
|
My HAL Pitch: There's lots of oil and gas left in the earth's crust, but nowadays, it takes more effort to prize it out. That's where Halliburton comes in.
|
||||||||||
| KKR | KKR & Co | 103.15 | 0.93 | 0.91% | 05/18/2015 | |||||
|
My KKR Pitch: In a world where the Democrats have overregulated the banks, freer sources of capital such as private equity should do the best. Their high distribution is excellent source of new investment cash at times.
|
||||||||||
| MCHP | Microchip Technology | 91.5 | 0.02 | 0.02% | 01/07/2015 | |||||
|
My MCHP Pitch: Makes digital chip products to make cars smarter inter alia. Best dividend payer in tech.
|
||||||||||
| MNTA | Momenta Pharmaceuticals, Inc. | 06/22/2017 | ||||||||
|
My MNTA Pitch: Cash = $6.33 per share; through Shire's acquisition of Baxter, solely own P3-proven Humira FOB; 20 mg Copaxone copy is only approved sole generic since Q4 2015; they await approval of more popular 40 mg version in 2H 2017. M281, now in P1 is superlative agonist for circulating fcn ABs.
|
||||||||||
